Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using
177Lu-radioligand therapy
PSMA
preclinical biodistribution, dosimetry
prostate cancer
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
10
08
2020
accepted:
04
12
2020
pubmed:
15
1
2021
medline:
6
1
2022
entrez:
14
1
2021
Statut:
ppublish
Résumé
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are applicable as radiochemical twins for both diagnostic PET imaging and endoradiotherapy. On the basis of preliminary data as a diagnostic ligand, the isomer rhPSMA-7.3 is a promising candidate for potential endoradiotherapy. The aim of this preclinical evaluation was to assess the biodistribution, dosimetry, and therapeutic efficacy of
Identifiants
pubmed: 33443072
pii: jnumed.120.254516
doi: 10.2967/jnumed.120.254516
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1106-1111Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.